SALT LAKE CITY, Feb. 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN - News) announced today that Jim Evans, Chief Financial Officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference, at 11:00 a.m. Eastern Time on Thursday, February 16, 2012. The conference is being held at the Waldorf Astoria Hotel in New York, New York.

The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at http://www.myriad.com.

About Myriad Genetics

Myriad Genetics, Inc. (Nasdaq:MYGN - News) is a leading molecular diagnostic company dedicated to developing and marketing transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess a patient's risk of disease progression and disease recurrence. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease. With fiscal year 2011 annual revenue of over $400 million and more than 1,000 employees, Myriad is working on strategic directives, including new product introductions, companion diagnostics, and international expansion, to take advantage of significant growth opportunities. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

More:
Myriad Genetics to Present at the Leerink Swann 2012 Global Healthcare Conference

Comments are closed.